Clinical Trial Update: Docetaxel or Hormone Therapy as Second Line Treatment in Patients With Asymptomatic or Oligosymptomatic Metastatic Castration-resistent Prostate Cancer (mCRPC) Progressing After Abiraterone or Enzalutamide. [Phase 3]

View source ↗

Summary

A Phase 3 trial comparing docetaxel versus hormone therapy as second-line treatment for asymptomatic or oligosymptomatic metastatic castration-resistant prostat…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer

Drugs mentioned

• DOCETAXEL (DOCETAXEL)
• Hormone therapy

Snippet

Sponsor: National Cancer Institute, Naples | Conditions: Metastatic Castration-resistent Prostate Cancer | Phase 3 | Status: UNKNOWN